Compare Bank of Nova Scotia (BNS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Zoetis Inc — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $108.32B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Bank of Nova Scotia is far larger — about 3.5× Zoetis Inc's market cap, and Bank of Nova Scotia pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| BNS | ZTS | |
|---|---|---|
Market Cap | $108.32B | $31.14B |
Sector | Financials | Health |
52-Week High | $90.29 | $156.76 |
52-Week Low | $56.41 | $71.91 |
Dividend Yield | 3.64% | 2.81% |
Enterprise Value | — | $38.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $90.34, up 2.01% with a bullish technical outlook supported by moving averages. The bank has delivered three consecutive earnings beats, with Q2 2026 EPS expected at $1.53. Recent acquisition of MapleMark Bank and dividend increase to $1.14 demonstrate strategic growth initiatives. Valuation metrics show P/E of 17.1 and P/B of 1.96, while maintaining strong profitability with 24.86% net income margin.
BNS presents a compelling investment case with strong fundamentals and analyst support (52.63% buy ratings), though revenue growth has been modest and interest expenses remain elevated. The stock faces risks from economic uncertainty and credit quality concerns, but dividend stability and improving ROE to 11.87% provide downside protection. Upside potential exists if the bank maintains earnings momentum.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
